Clozapine (sold as Clozaril®, Leponex®, Fazaclo®) was the first of the atypical antipsychotics to be developed. It was approved by the United States Food and Drug Administration (FDA) in 1989 and is the only FDA-approved medication indicated for treatment-resistant schizophrenia and for reducing the risk of suicidal behaviour in patients with schizophrenia.
Antipsychotics :: Drugs and Medications

Clozapine - Fact sheet about this schizophrenia medication, from NAMI. Covers benefits, side effects, risks, and other topics.
Clozaril - Novartis - Official pharmaceutical website for canadian consumers and health care professionals.
Meta Description: [ Novartis Pharmaceuticals Canada Inc. - Our Products - Clozaril ]
Focus on Clozapine - Review article about this atypical antipsychotic medication, by Dr. Miriam Naheed, Hollins Park Hospital, and Dr. Ben Green, Royal Liverpool University Hospital.
Meta Description: [ Review article about clozapine and atypical antipsychotic ]
MedlinePlus: Clozapine - Provides information on usage, precautions, side effects and brand names when available. Data provided by various government agencies and health-related organizations.
Meta Description: [ Clozapine ]
The ZGP National Clozapine Registry - U.S. national program for monitoring patients who are receiving clozapine. Site includes information about the risks and contraindications being monitored.
| Alert on Atypical Antipsychotics (June 2005) | |
| Next Video | |